Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380610 · ClinicalTrials.gov registry record
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 120
- Enrollment target
NCT04380610: Completed study, sponsored by University of Alabama at Birmingham.
NCT04380610 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04380610 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
Primary Outcome
The investigators will use biologically relevant variables to develop a new equation for eGFR in pediatric and adult sickle cell patients
Interventions
- DIAGNOSTIC_TEST iohexol GFR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2025-06-30 |
What the finished NCT04380610 record still lists
NCT04380610 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which iohexol GFR is the first listed.
NCT04380610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04380610 about?
NCT04380610 is a clinical study titled "Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia". The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
What is the current status of trial NCT04380610?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2021-05-12. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04380610?
The interventions under investigation include: iohexol GFR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04380610?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI